Interleukin-2 targeted fusion toxin using parts of the diphtheria toxin data

SRGN (Hopkinton, Mass.) and collaborators published early results of an ongoing Phase I/II trial showing a marked response in some patients.

As reported in Nature Medicine, the data from the open-label study suggest that the disease is due to overactive T cells, rather than keratinocytes, and in fact resembles a misdirected activation of the immune responses brought to bear in wound healing. ...